CRISPR Therapeutics AG (CRSP) Current Assets (2015 - 2026)
CRISPR Therapeutics AG (CRSP) posted Current Assets of $2.4 billion for Q1 2026, up 23.3% sequentially from $2.0 billion in Q4 2025, and up 31.1% YoY from $1.9 billion in Q1 2025.
CRISPR Therapeutics AG (CRSP) Current Assets (2015 - 2026) Analysis & Trends
CRISPR Therapeutics AG has reported Current Assets for 12 years, with the latest figure at $2.4 billion in Q1 2026.
- Quarterly Current Assets rose 31.1% year-over-year to $2.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 31.1% YoY) and the FY2025 annual result came in at $2.0 billion, up 2.51% from the prior year.
- Current Assets advanced to $2.4 billion in Q1 2026 per CRSP's latest filing, from $2.0 billion in the prior quarter.
- Over five years, Current Assets peaked at $2.4 billion in Q1 2026 and troughed at $1.7 billion in Q2 2025.
- A 5-year average of $2.0 billion and a median of $1.9 billion in 2022 frame the typical range for Current Assets.
- The sharpest annual moves came in 2022 and 2026: Current Assets dropped 23.35% in 2022, then surged 31.1% in 2026.
- Over 5 years, Current Assets stood at $1.9 billion in 2022, then increased by 2.97% to $1.9 billion in 2023, then grew by 1.52% to $1.9 billion in 2024, then grew by 2.51% to $2.0 billion in 2025, then climbed by 23.3% to $2.4 billion in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $2.4 billion, $2.0 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 2.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.37 Bn |
| Mar 31, 2026 | 2.45 Bn |
| Dec 31, 2025 | 1.99 Bn |
| Sep 30, 2025 | 1.93 Bn |
| Jun 30, 2025 | 1.73 Bn |
| Mar 31, 2025 | 1.87 Bn |
| Dec 31, 2024 | 1.94 Bn |
| Sep 30, 2024 | 1.94 Bn |
| Jun 30, 2024 | 2.01 Bn |
| Mar 31, 2024 | 2.12 Bn |
| Dec 31, 2023 | 1.91 Bn |
| Sep 30, 2023 | 1.76 Bn |
| Jun 30, 2023 | 1.86 Bn |
| Mar 31, 2023 | 1.91 Bn |
| Dec 31, 2022 | 1.85 Bn |
| Sep 30, 2022 | 1.93 Bn |
| Jun 30, 2022 | 2.11 Bn |
| Mar 31, 2022 | 2.26 Bn |
| Dec 31, 2021 | 2.42 Bn |
| Sep 30, 2021 | 2.52 Bn |